Amarin (NASDAQ:AMRN) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Amarin (NASDAQ:AMRN) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.11, Zacks reports. The business had revenue of $39.55 million during the quarter, compared to analysts’ expectations of $43.76 million. Amarin had a negative net margin of 10.87% and a negative return on equity of 0.52%.

Here are the key takeaways from Amarin’s conference call:

• Positive Sentiment: Amarin reported its first profitable quarter in two years, with Q3 net income of $245,000 versus a $7.7 million loss a year earlier, $9 million in positive operating cash flow, and $324 million in cash and investments with no debt.
• Positive Sentiment: International momentum remained strong: European VAZKEPA in-market demand rose an estimated 68% year over year, total global partner demand increased 55%, and launches in Poland, Singapore, and South Korea are expanding the commercial opportunity.
• Negative Sentiment: Q3 revenue fell to $39.6 million from $49.7 million, primarily because U.S. pricing pressure and generic competition reduced net selling prices despite stable branded prescription volume; management expects pricing pressure to continue into 2027.
• Positive Sentiment: Amarin maintained a 47% share of the U.S. IPE market, reduced operating expenses by 44% year over year, improved gross margins sequentially through renegotiated supply contracts, and expects positive operating cash flow for the full year.
• Neutral Sentiment: The investigator-led EMT-2 colorectal cancer trial did not meet its primary progression-free-survival endpoint but showed a statistically significant 32% reduction in the hazard of death on overall survival; Amarin is evaluating the data and potential commercial and development paths, including possible partnerships.

Amarin Trading Down 5.2%

AMRN stock opened at $12.07 on Friday. The stock has a market cap of $254.92 million, a P/E ratio of -12.57 and a beta of 0.76. Amarin has a twelve month low of $11.25 and a twelve month high of $17.31. The company’s 50 day moving average is $12.97 and its two-hundred day moving average is $14.32.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AMRN. Weiss Ratings reissued a “sell (d-)” rating on shares of Amarin in a report on Thursday, October 15th. Wall Street Zen raised Amarin from a “hold” rating to a “buy” rating in a report on Saturday. JPMorgan Chase & Co. initiated coverage on Amarin in a report on Friday, August 21st. They set an “underweight” rating and a $13.00 price target for the company. Finally, Zacks Research raised Amarin from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $13.00.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapies intended to reduce cardiovascular risk. Its principal product is VASCEPA (icosapent ethyl), a prescription omega-3 fatty-acid medicine derived from highly purified eicosapentaenoic acid.

VASCEPA was initially approved in the United States to help lower triglyceride levels in certain patients and later received expanded approval to reduce the risk of cardiovascular events in eligible adults with elevated cardiovascular risk.